China Grand Enterprises Ranks 15 at Top 100 Accolade in China's Pharmaceutical Industry
Hong Kong, 14 July, 2015
The 32nd China Pharmaceutical Industry Information Annual Conference 2015 was recently held in Chengdu by China National Pharmaceutical Industry Information Center. During the Conference, "Top Accolade in China's Pharmaceutical Industry in 2014" was officially announced. China Grand Enterprises, Inc. (China Grand Enterprises) ranks at 15 (exclude Hangzhou East China Pharmaceutical Group Co., Ltd).
According to the statistics and analysis from China National Pharmaceutical Industry Information Center, comparing to the standard calculation, the revenue of the Top 100 pharmaceutical enterprises in 2014 increased in 16.5%, 3.4% higher comparing with the industry average, total profits has an increment of 14.4%. The Top 100 Accolade in China's Pharmaceutical Industry is the only official data that reflects the economic situation in China's pharmaceutical industry, by ranking the top 100 pharmaceutical companies based on their revenue generated from pharmaceutical businesses.
China Grand Enterprises attaches great importance to the pharmaceutical and healthcare business, actively support the development of its pharmaceutical sector, since 2014, paying more attention to the development opportunities of international pharmaceutical market. China Grand Pharmaceutical and Healthcare Holdings Limited (China Grand Pharm, stockcode: 00512) is the only international capital market platform to China Grand Enterprises, started to research and follow international pharmaceutical market development opportunities in 2014, and in May 2015, the pursuant to the acquisition of Cardionovum GmbH with CDB Equipment Manufacturing Investment Fund Co. Ltd, the Company engages in the development, manufacturing and distribution of advanced interventional cardiovascular medical devices such as coronary drug eluting stent (DES) and drug-eluting balloons (DEB), taking this opportunity, China Grand Pharmaceutical and Healthcare Holdings Limited, soon will take action on internationalization strategy and international markets, with more successful records, to provide fruitful return to the shareholders.
China Grand Enterprises Inc.
China Grand Enterprises Limited has a broad spectrum in pharmaceutical and healthcare sector, including HK-listed company China Grand Pharmaceutical and Healthcare Holdings Limited (stockcode: 00512) engages in pharmaceutical preparations such as cerebro-cardiovascular and ophthalmic; another Shenzhen-listed company Huadong Medicine Co. Limited (stockcode: 00963) engages in products in diabetic and immune system. For non-listed assets, Lei Yunshang Pharmaceutical Group owns a Chinese medicine brand with a historical 300-year of history, a platform for Chinese medicine development and Sichuan Grand Shuyang Pharmaceutical Co., Ltd engages in production in blood plasma-based medicines, vaccines and recombinant biopharmaceutical products, a platform for biopharmaceutical development; to provide and develop the following 3 varieties, chemical pharmaceutical preparations, Chinese medicines and blood-plasma-based medicines and bio-chemical based vaccines.
